Filtered By:
Vaccination: Vaccines
Countries: Canada Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Ontario man speaks out after father has severe stroke from rare blood clot following AstraZeneca vaccine
An Ontario man whose father suffered a severe stroke from a rare blood clot after receiving the AstraZeneca-Oxford COVID-19 vaccine is revealing new details about the condition for the first time in hopes of helping Canadians better understand the risk.
Source: CBC | Health - April 24, 2021 Category: Consumer Health News Tags: News/Health Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study
Conclusions
Our estimated background rates help contextualise observed events of these potential adverse events of special interest and to detect potential safety signals related to COVID-19 vaccines.
Source: BMJ Open - December 17, 2021 Category: General Medicine Authors: Nasreen, S., Calzavara, A. J., Sundaram, M. E., MacDonald, S. E., Righolt, C. H., Pai, M., Field, T. S., Zhou, L. W., Wilson, S. E., Kwong, J. C. Tags: Open access, Public health, COVID-19 Source Type: research
CNS Summit 2017 Abstracts of Poster Presentations
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period.
Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.
Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF
Presenter: Chelsky...
Source: Innovations in Clinical Neuroscience - November 1, 2017 Category: Neuroscience Authors: ICNS Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research
Descriptive analysis of pharmacy services provided after community pharmacy screening
Conclusions Approximately one-third of participants received a pharmacy service within 3 months post-screening. Relatively large numbers of annual and follow-up medication reviews were delivered despite low eligibility for annual-only reviews and despite many missed opportunities for pharmacy service provision in at-risk patients. In-pharmacy screening may facilitate provision of some services, namely medication reviews, by providing opportunities to identify patients at-risk.
Source: International Journal of Clinical Pharmacy - November 26, 2018 Category: Drugs & Pharmacology Source Type: research
Barilla Foundation Brings Health and Climate Together in New Double Pyramid
The Barilla Foundation New Double Pyramid includes seven cultural pyramids including ones for specific regions like South Asia where these rice workers come from. Other cultural regions include Latin America, East Asia, Nordic and Canada, USA, Mediterranean and Africa.
Credit: Deepak Kumar / Unsplash By Alison KentishNEW YORK, Apr 12 2021 (IPS) Following an extensive scientific review, the Barilla Center for Food and Nutrition Foundation (BCFN) is preparing to launch a new food systems model which incorporates nutrition and climate.
Researchers from the Foundation teamed up with counterparts from the Frederico II Univers...
Source: IPS Inter Press Service - Health - April 12, 2021 Category: International Medicine & Public Health Authors: Alison Kentish Tags: Climate Change Economy & Trade Environment Featured Food & Agriculture Food Security and Nutrition Food Sustainability Global Headlines Health Humanitarian Emergencies Natural Resources TerraViva United Nations Barilla Center for Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
After she lost her hair from COVID-19, 7-year-old Regina girl excited for 1st vaccine dose
Cedar Herle was eager to get the pediatric COVID-19 vaccine after experiencing first-hand the long-term effects of the disease. She lost all of her hair after contracting COVID-19 a year ago, while her mother suffered a COVID-related stroke.
Source: CBC | Health - December 14, 2021 Category: Consumer Health News Tags: News/Canada/Saskatchewan Source Type: news
After she lost her hair from COVID-19, 7-year-old Regina girl excited about 1st vaccine dose
Cedar Herle was eager to get the pediatric COVID-19 vaccine after experiencing first-hand the long-term effects of the disease. She lost all of her hair after contracting COVID-19 a year ago, while her mother suffered a COVID-related stroke.
Source: CBC | Health - December 14, 2021 Category: Consumer Health News Tags: News/Canada/Saskatchewan Source Type: news
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research
Getting a flu vaccine lowers your risk of a STROKE years later, study shows
Researchers analyzed the health records of more than 4million adults in Alberta, Canada, over a 10-year period in the biggest study of its kind into the link between flu and strokes.
Source: the Mail online | Health - November 4, 2022 Category: Consumer Health News Source Type: news
The trends and determinants of seasonal influenza vaccination after cardiovascular events in Canada: a repeated, pan-Canadian, cross-sectional study
CONCLUSION: Influenza vaccination is still at less than the recommended level in patients with CVD. Future research should consider the impact of interventions to improve vaccination uptake in this population.PMID:36794825 | DOI:10.24095/hpcdp.43.2.04
Source: Health Promotion and Chronic Disease Prevention in Canada - February 16, 2023 Category: International Medicine & Public Health Authors: Hanna Cho Sherilyn J D Houle Wasem Alsabbagh Source Type: research
The 3rd Beijing Forum of Evidence-Based Medicine and 2023 Cochrane China Network Symposium successfully held
Cochrane China recently hosted a virtual event for the evidence-based medicine community that brought together many of its partners, local expertise, and international speakers. Here the team provides an overview of who was involved and what was covered at the event. The3rd Beijing forum of evidence-based medicine and Cochrane China Network Symposium was successfully held virtually on January 15th, 2023. The host of this conference wereCochrane China Network and Beijing GRADE Center. The organizers are Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, affiliate of the Cochrane China Ne...
Source: Cochrane News and Events - February 17, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news
